Cover Image
市場調查報告書

Intercept Pharmaceuticals, Inc.:產品平台分析

Intercept Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251678
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Intercept Pharmaceuticals, Inc.:產品平台分析 Intercept Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 34 Pages
簡介

是總公司位於美國的生物製藥企業,正在開發並商品化慢性肝炎及腸道疾病治療藥。該公司的先導化合物Obeticholic Acid(OCA)是類膽汁酸,藉由促進與法尼酯X受體結合的活性來治療原發性膽汁性肝硬化和非酒精性脂肪性肝炎等慢性自體免疫系肝疾病。

本報告提供Intercept Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Intercept Pharmaceuticals, Inc.的基本資料

  • Intercept Pharmaceuticals, Inc.概要
  • 主要資訊
  • 企業資料

Intercept Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Intercept Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Intercept Pharmaceuticals, Inc.:開發中產品概況

  • 後期階段產品開發中產品
    • 登記申請前的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Intercept Pharmaceuticals, Inc.:藥物簡介

  • obeticholic acid
  • INT-767
  • INT-777

Intercept Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Intercept Pharmaceuticals, Inc.:最近的開發平台形勢

Intercept Pharmaceuticals, Inc.:開發暫停中的計劃

Intercept Pharmaceuticals, Inc.:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07503CDB

Summary

Global Markets Direct's, 'Intercept Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Intercept Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Intercept Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Intercept Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Intercept Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Intercept Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Intercept Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Intercept Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Intercept Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Intercept Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Intercept Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Intercept Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Intercept Pharmaceuticals, Inc. Snapshot
    • Intercept Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Intercept Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Intercept Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Intercept Pharmaceuticals, Inc. - Pipeline Products Glance
    • Intercept Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • Intercept Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Intercept Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Intercept Pharmaceuticals, Inc. - Drug Profiles
    • obeticholic acid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-767
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-777
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Intercept Pharmaceuticals, Inc. - Pipeline Analysis
    • Intercept Pharmaceuticals, Inc. - Pipeline Products by Target
    • Intercept Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Intercept Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Intercept Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Intercept Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Intercept Pharmaceuticals, Inc. - Dormant Projects
  • Intercept Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Intercept Pharmaceuticals, Inc., Key Information
  • Intercept Pharmaceuticals, Inc., Key Facts
  • Intercept Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Intercept Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Intercept Pharmaceuticals, Inc. - Pre-Registration, 2015
  • Intercept Pharmaceuticals, Inc. - Phase II, 2015
  • Intercept Pharmaceuticals, Inc. - Phase I, 2015
  • Intercept Pharmaceuticals, Inc. - Preclinical, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Intercept Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Intercept Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Intercept Pharmaceuticals, Inc., Other Locations

List of Figures

  • Intercept Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Intercept Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Intercept Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top